Bibliographic Info
GuidelineWHO policy on collaborative TB/HIV activities : guidelines for national programmes and other stakeholders
Year of Publication2012
Issuing InstitutionWHO
Recommendation
Status
Maintained
Recommended in favor
Strong
Certainty of evidence
High
Efavirenz should be used as the preferred non-nucleoside reverse transcriptase inhibitor in patients starting ART while on antituberculosis treatment
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings : towards universal access : recommendations for a public health approach
Year2006
InstitutionWorld Health Organization